1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
BioGaia AB (publ)

BioGaia AB (publ)

BIOGY
BioGaia AB (publ)US flagOther OTC
11.00
USD
- -
- -
1.11BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.65
5.58
5.58
6.17
7.1
8.56
8.79
8.37
7.77
10.93
12.84
14.08
15.2
14.24
Basic EPS, GAAP
0.71
1.71
1.4
2.63
2.08
2.48
2.14
2.01
1.94
3.7
3.62
3.48
3.29
2.83
Free Cash Flow per Basic Share
0.71
1.16
1.03
1.64
2.26
1.96
1.25
2.3
2.13
2.98
3.74
3.55
2.99
3.07
Dividend per Share
2
1.4
1
1.43
1.5
1.8
1.98
0.73
0.68
2.98
2.9
6.89
6.9
6.9
Book Value per Share
3.61
3.92
4.32
4.53
5.08
5.56
5.54
6.71
7.16
7.85
8.53
5.06
1.42
- -
Tangible Book Value per Share
3.67
3.92
4.38
4.79
5.35
5.27
5.15
18.94
16.64
17.38
18.01
15.32
11.54
9.89
Basic Weighted Avg Shares
86
86
87
87
87
87
87
89
101
101
101
101
101
101
Sales/Revenue/Turnover
316
482
483
535
615
742
768
747
785
1,104
1,297
1,423
1,538
1,440
Operating Margin (%)
25.28
39.26
35.4
36.47
38.78
37.12
32.54
32.73
30.89
30.3
34.01
28.77
29.38
24.33
Depreciation Expense
6
6
7
7
7
8
16
21
27
24
25
26
25
77
Net Income, GAAP
62
147
121
228
181
215
187
180
196
374
365
351
333
287
Effective Tax Rate (%)
23.37
23.13
22.81
18.72
22.48
22.83
22.7
21.03
22.33
16.5
22.07
21.53
21
21.21
Profit Margin (%)
19.54
30.59
25.12
42.56
29.36
28.97
24.38
24.06
25
33.86
28.18
24.7
21.63
19.91
Working Capital
257
262
288
312
343
349
328
1,555
1,625
1,632
1,679
1,404
1,020
854
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
317
345
396
415
464
508
508
1,746
1,877
1,972
2,030
1,724
1,314
1,155
Return on Invested Capital (%)
15.2
41.6
35.26
38.93
41.59
42.6
36.84
16.91
10.31
14.39
16.99
16.9
23.47
20.22
Return on Capital (%)
15.56
45.15
34.11
59.5
43.43
46.67
38.45
32.72
29.36
49.55
44.26
51.38
103.12
14,982,806.04
Return on Common Equity (%)
16.27
45.3
34.09
59.42
43.38
46.62
38.8
33.2
29.69
49.3
44.18
51.21
101.66
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
11,228
10,599
8,633

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,610
1,629
1,034
Cash, Cash Equivalents & STI
1,224
1,249
622
Accounts Receivable, Net
190
- -
- -
Inventories
153
- -
- -
Total Current Liabilities
206
150
180
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.66%
-4.67%
-23.77%
Free Cash Flow
18.54%
9.92%
-15.62%
Net Income, GAAP
15.72%
17.65%
-5.3%
Sales/Revenue/Turnover
12.81%
16.2%
8.11%
Total Cash Common Dividend
49.59%
95.75%
0.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
370
384
304
365
1,423
2025
366
405
441
- -
1,538
2026
373
441
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.21
1.1
0.36
0.81
3.48
2025
0.79
0.87
0.98
- -
3.29
2026
0.78
1.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
6.9
- -
- -
6.89
2025
- -
6.9
- -
- -
6.9
2026
- -
4
- -
- -
- -

Company Description

APIChatGPT
CEO
Theresa Agnew
Full Time Employees
243
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Kungsbroplan 3 Stockholm AB Sweden 112 27
IPO Date
Jan 8, 2021
CIK
0001572957
Website
biogaiagroup.com
Similar Companies
Caplin Point Laboratories Limited (CAPLIPOINT.NS)
Speakeasy Cannabis Club Ltd. (SPBBF)
Vifor Pharma AG (GNHAY)
HLS Therapeutics Inc. (HLTRF)
Biofrontera AG (BFRA)
Huons Co., Ltd. (243070.KQ)
Business
BioGaia AB (publ) develops, manufactures, markets and sells probiotic products based on patented Lactobacillus reuteri strains for gut health, immune health, oral health and bone health; its Pediatrics segment offers drops, oral rehydration solutions, gut health tablets and cultures used as ingredients in infant and milk formulas; the Adult Health segment provides gut health tablets, bone health tablets, oral health lozenges and cultures incorporated into licensees' dairy products; the Other segment supplies packaging solutions. Specific strains include L. reuteri Protectis (DSM 17938) for gut and immune applications such as infant colic, diarrhea prevention, H. pylori eradication and general illness prevention, and L. reuteri Prodentis (DSM 17938 and ATCC PTA 5289) for gingivitis and periodontal disease. Products are sold under the BioGaia brand or via co-branding through distribution partners and subsidiaries in over 100 countries across EMEA (Europe, Middle East, Africa), Americas (USA, Canada, South America) and APAC (Asia-Pacific). Founded in 1990 and headquartered in Stockholm, Sweden, the company employs 225 people and invests about 11% of net sales in research and development, supported by over 270 published studies, 600 granted patents and 35 years of microbiome innovation. In July 2025, BioGaia launches subsidiary BioGaia New Sciences AB to advance microbiome research into new areas including skin health biotics beyond core probiotic focuses, with no material financial impact; in November 2024, Anatom Holding AG acquires a 4.9% shareholding following EQT Public Value fund's exit; in 2025, the company publishes data on new patented strain L. reuteri BG-R46 for upcoming baby drops and reports Q3 net sales growth of 7% to SEK 326.6 million, with Pediatrics up 7%.

Company News

APIChatGPT

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q3 2025 Earnings Call Transcript